Germany Joins Decision To Suspend AZ Vaccine Over Safety, But Is It Really The Most ‘Cautious’ Approach?
Countries At Odds With EMA Guidance
AstraZeneca’s vaccine is under suspicion again, this time over safety, rather than efficacy, and the European Medicines Agency has promised a swift review.
You may also be interested in...
Comment: While the travails around the COVID-19 vaccine continue, AstraZeneca has plenty in its pipeline to cheer investors.
GSK looks to Cabenuva to get ahead in the long-acting HIV therapy and PrEP market, but Gilead will not relinquish its lead easily.
While news of a potentially highly transmissible new variant is causing alarm, Pfizer/BioNTech and Moderna are already pursuing a multi-pronged response to B.1.1.529.